03-0203-00
SMC® Human GFAP High Sensitivity Immunoassay Kit
Used for ultrasensitive quantification of Human GFAP in human serum, plasma, and cerebrospinal fluid (CSF)
别名:
GFAP Single Molecule Counting Kit, GFAP ultra-sensitive immunoassay, Glial fibrillary acidic protein immunoassay kit
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
NACRES:
NA.77
UNSPSC Code:
12161503
Species reactivity:
human
Usage:
kit sufficient for 96 wells
Compatibility:
for use with FemtoQuest™ and SMCxPRO® instruments
产品名称
SMC® Human GFAP High Sensitivity Immunoassay Kit,
Quality Segment
description
Used for ultrasensitive quantification of Human GFAP in human serum, plasma, and cerebrospinal fluid (CSF)
product line
SMC®
usage
kit sufficient for 96 wells
species reactivity
human
input
serum
cerebrospinal fluid (CSF)
plasma (K2 EDTA)
UniProt accession no.
compatibility
for use with FemtoQuest™ and SMCxPRO® instruments
shipped in
wet ice
storage temp.
2-8°C
General description
Glial fibrillary acidic protein (GFAP) is a key intermediate filament protein predominantly expressed in astrocytes, a type of glial cell in the central nervous system. GFAP plays a vital role in maintaining the structural integrity of astrocytes and supporting their functions, including the regulation of the extracellular environment, the provision of metabolic support to neurons, and the modulation of synaptic activity.
GFAP serves as an important biomarker for astrocyte activation and neuroinflammation. Elevated levels of GFAP in cerebrospinal fluid (CSF) and blood may indicate reactive astrogliosis, a condition often associated with brain injury, multiple sclerosis, Alzheimer′s disease, and other neurodegenerative disorders. As increased GFAP levels often reflect the extent of neuroinflammatory responses and neuronal damage, GFAP is a critical target to monitor when developing strategies aimed at mitigating neuroinflammation and preserving neuronal health.
GFAP serves as an important biomarker for astrocyte activation and neuroinflammation. Elevated levels of GFAP in cerebrospinal fluid (CSF) and blood may indicate reactive astrogliosis, a condition often associated with brain injury, multiple sclerosis, Alzheimer′s disease, and other neurodegenerative disorders. As increased GFAP levels often reflect the extent of neuroinflammatory responses and neuronal damage, GFAP is a critical target to monitor when developing strategies aimed at mitigating neuroinflammation and preserving neuronal health.
Application
Alzheimer′s Disease / Aging / Nervous System / Neurodegenerative Diseases / Neurofilament & Neuron Metabolism / Neuronal & Glial Markers / Neurodegenerative Medicine / Neuroscience
Features and Benefits
- Femtogram-Level Aβ1-42 Detection: Achieves exceptional sensitivity (fg/mL) in serum, plasma or CSF.
- Enhanced Signal Performance: Features a broadened dynamic range with reduced background noise, ensuring consistent results.
- Familiar Assay Format: Utilizes a standard sandwich immunoassay design merged with advanced sensitivity.
- Flexible Automation Integration: Incorporates with liquid handling systems to standardize workflows and further minimize variability.
- Specialized Technical Support: Supported by SMC® platform experts.
Packaging
96 well assay
Analysis Note
- Sensitivity: LLOQ 230 fg/mL* (SMCxPRO® Instrument)
- Standard Curve Range: 60-300,000 fg/mL
- Intra-assay CV: <15%
- Inter-assay CV: <20%
- Linearity: Serum: 101% Plasma: 99% CSF: 101%
- Recovery: Serum: 118% Plasma: 115% CSF: 101%
Other Notes
Although GFAP was detectable in non-human primate (rhesus macaque and cynomolgus monkey), feline, rat, mouse, and canine samples, the assay has not been verified for these species.
Legal Information
FEMTOQUEST is a trademark of Merck KGaA, Darmstadt, Germany
SMC is a registered trademark of Singulex
SMCxPRO is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
signalword
Danger
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - ED ENV 1 - Eye Irrit. 2 - Repr. 1B